Diakonos Oncology

Diakonos Oncology is a clinical-stage biotechnology company focused on revolutionizing cancer immunotherapy, particularly for difficult-to-treat cancers like glioblastoma. They develop dendritic cell vaccines (DCVs) using a proprietary double loading technology to initiate a complete cytotoxic T H 1 immune response against a patient's cancer. Their lead asset, DOC1021, is in Phase 2 clinical trials.

Buy Funded Startups lists

Funding Round: Seed

Funding Amount: $11.4M

Date: 26-Aug-2024

Investors: Restem Group Inc., existing investors

Markets: Immuno-oncology, Cell Therapy, Drug Discovery, Biotechnology

HQ: Houston, Texas, United States

Founded: 2016

Website: https://www.diakonosoncology.com/

LinkedIn: https://www.linkedin.com/company/diakonos-oncology

Twitter:

Instagram: